Provided by Tiger Fintech (Singapore) Pte. Ltd.

ZAI LAB

17.260
+0.0100.06%
Volume:12.68M
Turnover:217.23M
Market Cap:19.30B
PE:-8.55
High:17.370
Open:17.200
Low:16.940
Close:17.250
52wk High:35.500
52wk Low:16.810
Shares:1.12B
HK Float Shares:1.12B
Volume Ratio:0.65
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.019
ROE:-28.97%
ROA:-13.29%
PB:3.27
PE(LYR):-8.55
PS:5.62

Loading ...

Company Profile

Company Name:
ZAI LAB
Exchange:
SEHK
Establishment Date:
2013
Employees:
1869
Office Location:
Building B,899 Halei Road,Pudong,Shanghai Province,China
Zip Code:
201203
Fax:
- -
Introduction:
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.

Directors

Name
Position
Samantha Du
Founder, Chief Executive Officer, Chairperson of the Board
John Diekman
Lead Independent Director
Leon O. Moulder, Jr.
Director
Michel Vounatsos
Director
Nisa Leung
Director
Peter Wirth
Director
Richard B. Gaynor
Director
Scott W. Morrison
Director
William Lis
Director

Shareholders

Name
Position
Samantha Du
Founder, Chief Executive Officer, Chairperson of the Board
Joshua Smiley
President and Chief Operating Officer
Yajing Chen
Chief Financial Officer
F. Ty Edmondson
Chief Legal Officer
Rafael G. Amado
President, Head of Global Research and Development